|
Variable
|
Whole cohort
|
Matched cohort
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
Diagnosis year
|
|
2000–2003
|
Ref.
| |
Ref.
| |
|
2004–2008
|
0.76 (0.72–0.80)
|
< 0.001
|
0.69 (0.56–0.86)
|
0.001
|
|
2009–2012
|
0.63 (0.57–0.69)
|
< 0.001
|
0.64 (0.45–0.92)
|
0.014
|
|
Race
|
|
NHW
|
Ref.
| |
Ref.
| |
|
NHB
|
1.51 (1.39–1.64)
|
< 0.001
|
1.27 (0.91–1.78)
|
0.157
|
|
NHAIAN
|
1.42 (1.01–1.99)
|
0.047
|
4.73 (1.16–19.27)
|
0.030
|
|
NHAPI
|
0.89 (0.79–0.99)
|
0.047
|
1.29 (0.83–2.00)
|
0.266
|
|
Hispanic
|
1.11 (1.01–1.22)
|
0.036
|
0.94 (0.61–1.44)
|
0.760
|
|
Unknown
|
0.45 (0.20–1.01)
|
0.050
|
0.00 (0.00–12.40)
|
0.925
|
|
Marital status
|
|
Married
|
Ref.
| |
Ref.
| |
|
Single
|
1.17 (1.08–1.27)
|
< 0.001
|
1.10 (0.78–1.57)
|
0.571
|
|
Widowed
|
1.26 (1.17–1.36)
|
< 0.001
|
1.25 (1.01–1.55)
|
0.045
|
|
Divorced
|
1.23 (1.13–1.33)
|
< 0.001
|
1.15 (0.82–1.62)
|
0.416
|
|
Unknown
|
1.14 (0.98–1.32)
|
0.095
|
0.97 (0.54–1.74)
|
0.914
|
|
Age (years)
|
|
18–49
|
Ref.
| |
Ref.
| |
|
50–64
|
0.96 (0.89–1.03)
|
0.200
|
0.69 (0.48–0.99)
|
0.042
|
|
65–79
|
1.69 (1.56–1.83)
|
< 0.001
|
1.13 (0.81–1.57)
|
0.466
|
|
80–
|
3.08 (2.74–3.46)
|
< 0.001
|
1.72 (1.23–2.41)
|
0.001
|
|
T stage
|
|
T1mic
|
Ref.
| |
Ref.
| |
|
T1a
|
1.29 (0.76–1.68)
|
0.065
|
1.35 (0.76–2.40)
|
0.309
|
|
T1b
|
1.78 (1.14–2.28)
|
< 0.001
|
1.94 (1.14–3.33)
|
0.015
|
|
T1c
|
2.93 (2.15–3.73)
|
< 0.001
|
3.62 (2.15–6.10)
|
< 0.001
|
|
Histological type
|
|
Ductal
|
Ref.
| |
Ref.
| |
|
Lobular
|
0.94 (0.87–1.01)
|
0.077
|
0.87 (0.67–1.13)
|
0.295
|
|
Favorable
|
0.61 (0.52–0.72)
|
< 0.001
|
0.99 (0.69–1.42)
|
0.966
|
|
Others
|
0.69 (0.57–0.83)
|
< 0.001
|
0.93 (0.46–1.88)
|
0.840
|
|
Grade
|
|
I
|
Ref.
| |
Ref.
| |
|
II
|
1.75 (1.62–1.90)
|
< 0.001
|
1.62 (1.27–2.06)
|
< 0.001
|
|
III
|
2.68 (2.45–2.93)
|
< 0.001
|
2.50 (1.89–3.32)
|
< 0.001
|
|
Unknown
|
1.81 (1.58–2.09)
|
< 0.001
|
1.32 (0.88–2.00)
|
0.180
|
|
ER
|
|
Negative
|
Ref.
| |
Ref.
| |
|
Positive
|
0.73 (0.67–0.80)
|
< 0.001
|
0.67 (0.48–0.92)
|
0.013
|
|
Unknown
|
0.69 (0.57–0.85)
|
< 0.001
|
0.38 (0.19–0.75)
|
0.006
|
|
PR
|
|
Negative
|
Ref.
| |
Ref.
| |
|
Positive
|
0.74 (0.69–0.79)
|
< 0.001
|
0.74 (0.57–0.97)
|
0.027
|
|
Unknown
|
1.00 (0.83–1.20)
|
0.998
|
1.48 (0.80–2.72)
|
0.213
|
|
Chemotherapy
|
|
No
|
Ref.
| |
Ref.
| |
|
Yes
|
1.49 (1.39–1.58)
|
< 0.001
|
1.29 (0.94–1.77)
|
0.115
|
|
Surgical axillary staging
|
|
No
|
Ref.
| |
Ref.
| |
|
Yes
|
0.68 (0.60–0.76)
|
< 0.001
|
0.70 (0.59–0.83)
|
< 0.001
|
- BCSS breast cancer-specific survival, HR hazard ratios, CI confidence intervals, NHW non-Hispanic white, NHB non-Hispanic black, NHAIAN non-Hispanic American Indian/Alaska native, NHAPI non-Hispanic Asian or Pacific Islander, ER estrogen receptor, PR progesterone receptor
